4d Molecular Therapeutics Stock Buy Hold or Sell Recommendation
| FDMT Stock | USD 4.11 0.17 3.97% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding 4D Molecular Therapeutics is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell 4D Molecular Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for 4D Molecular Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out 4D Molecular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as FDMT and provide practical buy, sell, or hold advice based on investors' constraints. 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
FDMT |
Execute 4D Molecular Buy or Sell Advice
The FDMT recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on 4D Molecular Therapeutics. Macroaxis does not own or have any residual interests in 4D Molecular Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute 4D Molecular's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
4D Molecular Trading Alerts and Improvement Suggestions
| 4D Molecular generated a negative expected return over the last 90 days | |
| 4D Molecular has high historical volatility and very poor performance | |
| 4D Molecular has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 37 K. Net Loss for the year was (160.87 M) with loss before overhead, payroll, taxes, and interest of (141.26 M). | |
| 4D Molecular Therapeutics currently holds about 241.09 M in cash with (134.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| 4D Molecular has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 11653 shares by Kirn David of 4D Molecular at 14.42 subject to Rule 16b-3 |
4D Molecular Returns Distribution Density
The distribution of 4D Molecular's historical returns is an attempt to chart the uncertainty of 4D Molecular's future price movements. The chart of the probability distribution of 4D Molecular daily returns describes the distribution of returns around its average expected value. We use 4D Molecular Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of 4D Molecular returns is essential to provide solid investment advice for 4D Molecular.
| Mean Return | -0.74 | Value At Risk | -8.61 | Potential Upside | 7.08 | Standard Deviation | 5.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of 4D Molecular historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
FDMT Stock Institutional Investors
The 4D Molecular's institutional investors refer to entities that pool money to purchase 4D Molecular's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Redmile Group, Llc | 2024-12-31 | 1.2 M | Casdin Capital, Llc | 2024-12-31 | 1.1 M | State Street Corp | 2024-12-31 | 1.1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Jpmorgan Chase & Co | 2024-12-31 | 820.1 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 794.6 K | Assenagon Asset Management Sa | 2024-12-31 | 653.5 K | Deep Track Capital, Lp | 2024-12-31 | 609.9 K | Citadel Advisors Llc | 2024-12-31 | 605.1 K | Blackrock Inc | 2024-12-31 | 4.9 M | Ra Capital Management, Llc | 2024-12-31 | 4.6 M |
4D Molecular Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 175K | 2.9M | (591K) | (4.5M) | (4.1M) | (3.9M) | |
| Investments | (1M) | (163.6M) | (5.5M) | 86.6M | (302.4M) | (287.3M) | |
| Change In Cash | 227.1M | (123.7M) | (100.7M) | 196.8M | (99.8M) | (94.8M) | |
| Free Cash Flow | (51.9M) | (78.2M) | (98.2M) | (78.6M) | (134.6M) | (127.9M) | |
| Depreciation | 1.4M | 3.0M | 3.9M | 5.7M | 6.7M | 7.0M | |
| Other Non Cash Items | 48K | 898K | 1.1M | (999K) | (7.1M) | (6.7M) | |
| Capital Expenditures | 1M | 9.1M | 11.5M | 2.8M | 3.8M | 4.5M | |
| Net Income | (56.7M) | (71.3M) | (107.5M) | (100.8M) | (160.9M) | (152.8M) | |
| End Period Cash Flow | 276.7M | 153.0M | 52.4M | 249.1M | 149.3M | 143.8M | |
| Change To Netincome | 8.7M | 5.1M | 14.7M | 17.1M | 19.7M | 20.7M |
4D Molecular Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to 4D Molecular or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that 4D Molecular's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a FDMT stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 0.83 | |
σ | Overall volatility | 5.32 | |
Ir | Information ratio | -0.12 |
4D Molecular Volatility Alert
4D Molecular Therapeutics exhibits very low volatility with skewness of -0.21 and kurtosis of 0.27. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure 4D Molecular's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact 4D Molecular's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.4D Molecular Fundamentals Vs Peers
Comparing 4D Molecular's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze 4D Molecular's direct or indirect competition across all of the common fundamentals between 4D Molecular and the related equities. This way, we can detect undervalued stocks with similar characteristics as 4D Molecular or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of 4D Molecular's fundamental indicators could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare 4D Molecular to competition |
| Fundamentals | 4D Molecular | Peer Average |
| Return On Equity | -0.39 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Current Valuation | (209.51 M) | 16.62 B |
| Shares Outstanding | 46.3 M | 571.82 M |
| Shares Owned By Insiders | 3.91 % | 10.09 % |
| Shares Owned By Institutions | 96.09 % | 39.21 % |
| Number Of Shares Shorted | 6.17 M | 4.71 M |
| Price To Book | 0.37 X | 9.51 X |
| Price To Sales | 5,143 X | 11.42 X |
| Revenue | 37 K | 9.43 B |
| Gross Profit | (141.26 M) | 27.38 B |
| EBITDA | (187.84 M) | 3.9 B |
| Net Income | (160.87 M) | 570.98 M |
| Cash And Equivalents | 241.09 M | 2.7 B |
| Cash Per Share | 7.45 X | 5.01 X |
| Total Debt | 24.61 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 17.20 X | 2.16 X |
| Book Value Per Share | 11.15 X | 1.93 K |
| Cash Flow From Operations | (134.59 M) | 971.22 M |
| Short Ratio | 5.58 X | 4.00 X |
| Earnings Per Share | (2.98) X | 3.12 X |
| Price To Earnings To Growth | (0.07) X | 4.89 X |
| Target Price | 33.82 | |
| Beta | 2.82 | -0.15 |
| Market Capitalization | 190.3 M | 19.03 B |
| Total Asset | 560.38 M | 29.47 B |
| Retained Earnings | (576.2 M) | 9.33 B |
| Working Capital | 405.78 M | 1.48 B |
| Net Asset | 560.38 M |
Note: Disposition of 11653 shares by Kirn David of 4D Molecular at 14.42 subject to Rule 16b-3 [view details]
4D Molecular Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as FDMT . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About 4D Molecular Buy or Sell Advice
When is the right time to buy or sell 4D Molecular Therapeutics? Buying financial instruments such as FDMT Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having 4D Molecular in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.